AnaptysBio Director John Orwin Receives 6,030 Shares from RSU Vesting

This Form 4 filing reports that John Orwin, a director of AnaptysBio, Inc., received 6,030 shares of common stock on June 15, 2026, through the vesting of restricted stock units (RSUs). The RSUs, which represented a contingent right to receive one share of common stock each, vested 100% on June 15, 2026, subject to Orwin's continued service to the company. Following this transaction, Orwin's total direct holdings increased to 16,695 shares of common stock. The shares were acquired at no cost to Orwin, as is typical with RSU settlements. The filing includes a power of attorney executed on June 17, 2026, authorizing company representatives to file Section 16 reports on Orwin's behalf.